MBX Biosciences appointed Steve Hoerter chairman and chief executive, effective immediately, succeeding Kent Hawryluk. Hoerter has served as executive chairman since November 2025 and joined the board ...

MBX Biosciences (MBX) announced on Monday that its Board of Directors has appointed Steve Hoerter, current executive chairman of the board, as its new chairman and chief executive officer, effective ...

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of ...

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

Lulu's Fashion Lounge Holdings formed a special committee to evaluate strategic alternatives. Shares surged 28% to $10.65 after-hours on Monday. MBX Biosciences appointed Steve Hoerter chief executive ...

MBX Biosciences develops precision peptide therapies targeting endocrine and metabolic disorders, with a pipeline including MBX 2109 (phase 2 for chronic hypoparathyroidism), MBX 1416 (phase 1 for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.

NYSEMKT: IEFA: $139.12 million (8.0% of AUM) NASDAQ: VONV: $101.89 million (5.9% of AUM) NASDAQ: VONG: $94.67 million (5.5% of AUM) NASDAQ: NVDA: $84.44 million (4.9% of AUM) NYSE: SGOV: $65.17 ...

Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candidate into ...

MBX Biosciences, Inc. (NASDAQ:MBX) stock traded higher on Monday after the company released clinically meaningful and statistically significant topline results from the once-weekly canvuparatide Phase ...